ACT-709478 clinical trials
Also written NBI-827104 and ACT-709478.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses ACT-709478 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Neurocrine Biosciences (3) · Idorsia Pharmaceuticals Ltd. (3)
Related medicines
As reviewed, each with the page that says it.
- One of Calcium channel blockers source
Studies
Open first, then newest update. How each study uses ACT-709478 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During SleepTerminatedPhase 2Neurocrine BiosciencesNCT05301894Written as NBI-827104
- Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During SleepCompletedPhase 2Neurocrine BiosciencesNCT04625101Written as NBI-827104
- Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential TremorCompletedPhase 2Neurocrine BiosciencesNCT04880616Written as NBI-827104
- A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy MenCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT04123288Written as ACT-709478
- Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03165097Written as ACT-709478
- A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy PatientsCompletedPhase 2Idorsia Pharmaceuticals Ltd.NCT03239691Written as ACT-709478 for oral use
Codes
What other systems call ACT-709478 · ClinicalTrials.gg INT001331
- MeSH (NLM) C000707407ACT-709478Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3Z7U1U8Z9EAPINOCALTAMIDEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000707407 | ACT-709478 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3Z7U1U8Z9E | APINOCALTAMIDE | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.